We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Among 2877 patients hospitalized for COVID-19, 29.5% had a history of hypertension, and the relative risk of mortality was increased by twofold in patients with hypertension compared with those without. Furthermore, those patients with a history of hypertension but not being treated with antihypertensives had a significantly higher risk of mortality compared with patients receiving antihypertensives. A meta-analysis showed that patients using RAAS inhibitors had a lower risk of mortality compared with those using other antihypertensive drugs.
There was no harm from RAAS inhibitor use in patients with COVID-19 according to the study results. Several questions regarding these data exist, such as what type of antihypertensive medication should be given to this patient population? Could such medication lessen their mortality risk? Also, will RAAS inhibitor use affect the risk of infection with the virus?
This abstract is available on the publisher's site.
It remains unknown whether the treatment of hypertension influences the mortality of patients diagnosed with coronavirus disease 2019 (COVID-19).
METHODS AND RESULTS
This is a retrospective observational study of all patients admitted with COVID-19 to Huo Shen Shan Hospital. The hospital was dedicated solely to the treatment of COVID-19 in Wuhan, China. Hypertension and the treatments were stratified according to the medical history or medications administrated prior to the infection. Among 2877 hospitalized patients, 29.5% (850/2877) had a history of hypertension. After adjustment for confounders, patients with hypertension had a two-fold increase in the relative risk of mortality as compared with patients without hypertension [4.0% vs. 1.1%, adjusted hazard ratio (HR) 2.12, 95% confidence interval (CI) 1.17-3.82, P = 0.013]. Patients with a history of hypertension but without antihypertensive treatment (n = 140) were associated with a significantly higher risk of mortality compared with those with antihypertensive treatments (n = 730) (7.9% vs. 3.2%, adjusted HR 2.17, 95% CI 1.03-4.57, P = 0.041). The mortality rates were similar between the renin-angiotensin-aldosterone system (RAAS) inhibitor (4/183) and non-RAAS inhibitor (19/527) cohorts (2.2% vs. 3.6%, adjusted HR 0.85, 95% CI 0.28-2.58, P = 0.774). However, in a study-level meta-analysis of four studies, the result showed that patients with RAAS inhibitor use tend to have a lower risk of mortality (relative risk 0.65, 95% CI 0.45-0.94, P = 0.20).
While hypertension and the discontinuation of antihypertensive treatment are suspected to be related to increased risk of mortality, in this retrospective observational analysis, we did not detect any harm of RAAS inhibitors in patients infected with COVID-19. However, the results should be considered as exploratory and interpreted cautiously.
Association of Hypertension and Antihypertensive Treatment With COVID-19 Mortality: A Retrospective Observational Study
Eur Heart J 2020 Jun 04;[EPub Ahead of Print], C Gao, Y Cai, K Zhang, L Zhou, Y Zhang, X Zhang, Q Li, W Li, S Yang, X Zhao, Y Zhao, H Wang, Y Liu, Z Yin, R Zhang, R Wang, M Yang, C Hui, W Wijns, JW McEvoy, O Soliman, Y Onuma, PW Serruys, L Tao, F Li